BACKGROUND AND OBJECTIVE: Achieving local control of gliomas with photodynamic therapy (PDT) requires the delivery of adequate light fluences to depths of 1-2 cm in the resection margin where the majority of local recurrences originate. This is clinically impractical with current single-shot, intraoperative PDT treatments due to the length of time required to deliver adequate fluences. Multiple or extended treatment protocols would therefore seem to be required. The response of human glioma spheroids to 5-aminolevulinic acid (ALA)-mediated PDT using single or, repetitive light delivery protocols was investigated at both low and ultra low fluence rates. STUDY DESIGN/ MATERIALS AND METHODS: Human glioma spheroids (400 microm diameter) were subjected to sub-threshold light fluence (1.5, 3, or 6 J cm(-2)) ALA-PDT consisting of four light delivery schemes: single treatment given over either 1 or 24 hours, repetitive treatment given either as four 1 hour light treatments separated by a 4 day interval, or 24 hours light delivery, consisting of four 24 hours treatments separated by a 3 day interval. Treatment efficacy was evaluated using a growth assay. In some cases, confocal microscopy was used to image cell viability. RESULTS: The repetitive and single light treatment protocols were most effective when delivered at ultra low (microW cm(-2)) fluence rates. In all cases, growth inhibition was light dose-dependent. The repetitive ultra low fluence rate treatment (1.5 J cm(-2); irradiance = 17 microW cm(-2)) light delivery protocol was the most effective resulting in total growth inhibition during the 2-week observation period. CONCLUSION: Ultra low light fluence rate ALA-PDT results in significant spheroid growth inhibition. Repeated administration of ALA was required during repetitive and/or protracted single PDT treatment protocols. The existence of a lower fluence rate limit, below which the efficacy of threshold light fluences diminish was not found in these studies. Lasers Surg. Med. 41:578-584, 2009. (c) 2009 Wiley-Liss, Inc.
BACKGROUND AND OBJECTIVE: Achieving local control of gliomas with photodynamic therapy (PDT) requires the delivery of adequate light fluences to depths of 1-2 cm in the resection margin where the majority of local recurrences originate. This is clinically impractical with current single-shot, intraoperative PDT treatments due to the length of time required to deliver adequate fluences. Multiple or extended treatment protocols would therefore seem to be required. The response of humanglioma spheroids to 5-aminolevulinic acid (ALA)-mediated PDT using single or, repetitive light delivery protocols was investigated at both low and ultra low fluence rates. STUDY DESIGN/ MATERIALS AND METHODS:Humanglioma spheroids (400 microm diameter) were subjected to sub-threshold light fluence (1.5, 3, or 6 J cm(-2)) ALA-PDT consisting of four light delivery schemes: single treatment given over either 1 or 24 hours, repetitive treatment given either as four 1 hour light treatments separated by a 4 day interval, or 24 hours light delivery, consisting of four 24 hours treatments separated by a 3 day interval. Treatment efficacy was evaluated using a growth assay. In some cases, confocal microscopy was used to image cell viability. RESULTS: The repetitive and single light treatment protocols were most effective when delivered at ultra low (microW cm(-2)) fluence rates. In all cases, growth inhibition was light dose-dependent. The repetitive ultra low fluence rate treatment (1.5 J cm(-2); irradiance = 17 microW cm(-2)) light delivery protocol was the most effective resulting in total growth inhibition during the 2-week observation period. CONCLUSION: Ultra low light fluence rate ALA-PDT results in significant spheroid growth inhibition. Repeated administration of ALA was required during repetitive and/or protracted single PDT treatment protocols. The existence of a lower fluence rate limit, below which the efficacy of threshold light fluences diminish was not found in these studies. Lasers Surg. Med. 41:578-584, 2009. (c) 2009 Wiley-Liss, Inc.
Authors: Henry Hirschberg; Dag R Sørensen; Even Angell-Petersen; Qian Peng; Bruce Tromberg; Chung-Ho Sun; Signe Spetalen; Steen Madsen Journal: J Environ Pathol Toxicol Oncol Date: 2006 Impact factor: 3.567
Authors: Arjen Bogaards; Abhay Varma; Kai Zhang; David Zach; Stuart K Bisland; Eduardo H Moriyama; Lothar Lilge; Paul J Muller; Brian C Wilson Journal: Photochem Photobiol Sci Date: 2005-04-14 Impact factor: 3.982
Authors: D J Robinson; H S de Bruijn; N van der Veen; M R Stringer; S B Brown; W M Star Journal: Photochem Photobiol Date: 1999-01 Impact factor: 3.421
Authors: Henry Hirschberg; Francisco A Uzal; David Chighvinadze; Michelle J Zhang; Qian Peng; Steen J Madsen Journal: Lasers Surg Med Date: 2008-10 Impact factor: 4.025
Authors: Patrizia Agostinis; Kristian Berg; Keith A Cengel; Thomas H Foster; Albert W Girotti; Sandra O Gollnick; Stephen M Hahn; Michael R Hamblin; Asta Juzeniene; David Kessel; Mladen Korbelik; Johan Moan; Pawel Mroz; Dominika Nowis; Jacques Piette; Brian C Wilson; Jakub Golab Journal: CA Cancer J Clin Date: 2011-05-26 Impact factor: 508.702
Authors: Diane Shin; Lina Nguyen; Mai T Le; David Ju; Jimmy N Le; Kristian Berg; Henry Hirschberg Journal: Photodiagnosis Photodyn Ther Date: 2019-05-07 Impact factor: 3.631
Authors: Imran Rizvi; Sriram Anbil; Nermina Alagic; Jonathan Celli; Jonathan P Celli; Lei Zak Zheng; Akilan Palanisami; Michael D Glidden; Brian W Pogue; Tayyaba Hasan Journal: Photochem Photobiol Date: 2013-04-04 Impact factor: 3.421
Authors: Patrícia M R Pereira; Naxhije Berisha; N V S Dinesh K Bhupathiraju; Rosa Fernandes; João P C Tomé; Charles Michael Drain Journal: PLoS One Date: 2017-05-17 Impact factor: 3.240